PCR test for COVID-19 in 1.5 hours

Fibrocystic mastopathy

Fibrocystic mastopathy (FCM) is the most common benign breast disease in women, most often associated with a change in the hormonal background of a woman, characterized by a change in the normal ratio of epithelial and connective tissue components in the structure of the breast.

The exact cause of fibrocystic mastopathy is unknown, but it is assumed that the main role in its development is played by reproductive hormones (especially estrogens).

FCM risk factors:

  • Early onset of menstruation
  • Late onset of menopause
  • It is also noted that FCM is more common in women with depression, severe anxiety and experiencing stressful situations

Symptoms of FCM:

  • Seals in the mammary gland that change in size depending on the phase of the menstrual cycle
  • Soreness and increased sensitivity of the breast
  • Green, colostrum (not bloody) discharge from the nipples

The above changes are most often detected in both mammary glands.

List of necessary examinations:

  • Consultation with an oncologist-mammologist, including discussion of disturbing symptoms, examination of the mammary glands, removal of the discharge from the nipple for cytological examination
  • Digital mammography (from 39-40 years old). With a radiologically dense background, a mammologist may recommend breast tomosynthesis
  • Ultrasound examination of the mammary glands (ultrasound)

The above methods of examination do not require special training.

Treatment of FCM:

The therapy is selected individually and largely depends on the features of the manifestation of FCM in each specific case.
Some patients report that limiting the consumption of caffeinated beverages, a low-fat diet, or taking dietary supplements with essential fatty acids (such as Omega-3) reduces the symptoms of fibrocystic mastopathy

FCM today is considered more as a condition, a feature of the structure of the breast. The current forecast is favorable. There are no restrictions on the usual activity. The presence of FCM does not increase the risk of breast cancer.

GBUZ Moscow Clinical Scientific Center named after Loginov MHD